Colin Johnston

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Chemicals & Drugs

Anatomy

Disorders

Procedures

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Tikellis C; Cooper M E; Bialkowski K; Johnston C I; Burns W C; Lew R A; Smith A I; Thomas M C
Developmental expression of ACE2 in the SHR kidney: a role in hypertension?
Jandeleit-Dahm Karin; Lassila Markus; Davis Belinda J; Candido Riccardo; Johnston Colin I; Allen Terri J; Burrell Louise M; Cooper Mark E
Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
Jandeleit-Dahm Karin A M; Tikellis Christos; Reid Christopher M; Johnston Colin I; Cooper Mark E
Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Colin Johnston (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2006: Tikellis C; Cooper M E; Bialkowski K; Johnston C I; Burns W C; Lew R A; Smith A I; Thomas M C
Developmental expression of ACE2 in the SHR kidney: a role in hypertension?
Kidney international 2006;70(1):34-41.
2005: Jandeleit-Dahm Karin; Lassila Markus; Davis Belinda J; Candido Riccardo; Johnston Colin I; Allen Terri J; Burrell Louise M; Cooper Mark E
Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
Journal of hypertension 2005;23(11):2071-82.
2005: Jandeleit-Dahm Karin A M; Tikellis Christos; Reid Christopher M; Johnston Colin I; Cooper Mark E
Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.
Journal of hypertension 2005;23(3):463-73.
2005: Burrell Louise M; Risvanis John; Kubota Eiji; Dean Rachael G; MacDonald Peter S; Lu Sai; Tikellis Christos; Grant Sharon L; Lew Rebecca A; Smith A Ian; Cooper Mark E; Johnston Colin I
Myocardial infarction increases ACE2 expression in rat and humans.
European heart journal 2005;26(4):369-75; discussion 322-4.
2004: Tikellis C; Johnston C I; Forbes J M; Burns W C; Thomas M C; Lew R A; Yarski M; Smith A I; Cooper M E
Identification of angiotensin converting enzyme 2 in the rodent retina.
Current eye research 2004;29(6):419-27.
2004: Burrell Louise M; Johnston Colin I; Tikellis Christos; Cooper Mark E
ACE2, a new regulator of the renin-angiotensin system.
Trends in endocrinology and metabolism: TEM 2004;15(4):166-9.
2003: Kubota Eiji; Dean Rachael G; Hubner Richard A; Casley David J; Johnston Colin I; Burrell Louise M
Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
Clinical science (London, England : 1979) 2003;105(3):339-45.
2003: Davis B J; Johnston C I; Burrell L M; Burns W C; Kubota E; Cao Z; Cooper M E; Allen T J
Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy.
Diabetologia 2003;46(7):961-71.
2003: Fabiani Maurice E; Hawkes David J; Frauman Albert G; Tikellis Chris; Johnston Colin I; Wilkinson-Berka Jennifer L
Regulation of angiotensin II receptors in the prostate of the transgenic (mRen-2)27 rat: effect of angiotensin-converting enzyme inhibition.
The international journal of biochemistry & cell biology 2003;35(6):973-83.
2003: Tikellis Christos; Johnston Colin I; Forbes Josephine M; Burns Wendy C; Burrell Louise M; Risvanis John; Cooper Mark E
Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.
Hypertension 2003;41(3):392-7.
2002: Naitoh Mareo; Risvanis John; Balding Leanne C; Johnston Colin I; Burrell Louise M
Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition.
Cardiovascular research 2002;54(1):51-7.
2002: Tikkanen Ilkka; Tikkanen Tuula; Cao Zemin; Allen Terri J; Davis Belinda J; Lassila Markus; Casley David; Johnston Colin I; Burrell Louise M; Cooper Mark E
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
Journal of hypertension 2002;20(4):707-14.
2002: Dinh Diem T; Frauman Albert G; Somers Gino R; Ohishi Mitsuru; Zhou Jialong; Casley David J; Johnston Colin I; Fabiani Maurice E
Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia.
The Journal of pathology 2002;196(2):213-9.
2001: Nassis L; Frauman A G; Ohishi M; Zhuo J; Casley D J; Johnston C I; Fabiani M E
Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia.
The Journal of pathology 2001;195(5):571-9.
2001: Kubota E; Dean R G; Hubner R A; Balding L C; Johnston C I; Burrell L M
Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
Current hypertension reports 2001;3 Suppl 2():S31-3.
2001: Dinh D T; Frauman A G; Casley D J; Johnston C I; Fabiani M E
Angiotensin AT(4) receptors in the normal human prostate and benign prostatic hyperplasia.
Molecular and cellular endocrinology 2001;184(1-2):187-92.
2001: Fabiani M E; Sourial M; Thomas W G; Johnston C I; Johnston C I; Frauman A G
Angiotensin II enhances noradrenaline release from sympathetic nerves of the rat prostate via a novel angiotensin receptor: implications for the pathophysiology of benign prostatic hyperplasia.
The Journal of endocrinology 2001;171(1):97-108.
2001: Fabiani M E; Sourial M; Thomas W G; Johnston C I; Johnston C I; Frauman A G
Angiotensin II enhances noradrenaline release from sympathetic nerves of the rat prostate via a novel angiotensin receptor: implications for the pathophysiology of benign prostatic hyperplasia.
The Journal of endocrinology 2001;171(1):97-108.
2001: Hubner R A; Kubota E; Casley D J; Johnston C I; Burrell L M
In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat.
Journal of hypertension 2001;19(5):941-6.
2001: Dinh D T; Frauman A G; Johnston C I; Fabiani M E
Angiotensin receptors: distribution, signalling and function.
Clinical science (London, England : 1979) 2001;100(5):481-92.
2001: Dinh D T; Frauman A G; Sourial M; Casley D J; Johnston C I; Fabiani M E
Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia.
Endocrinology 2001;142(3):1349-56.
2000: Burrell L M; Farina N K; Balding L C; Johnston C I
Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure.
Hypertension 2000;36(6):1105-11.
2000: Burrell L M; Droogh J; Man in't Veld O; Rockell M D; Farina N K; Johnston C I
Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
American journal of hypertension 2000;13(10):1110-6.
2000: Fabiani M E; Dinh D T; Nassis L; Casley D J; Johnston C I
Comparative in vivo effects of irbesartan and losartan on angiotensin II receptor binding in the rat kidney following oral administration.
Clinical science (London, England : 1979) 2000;99(4):331-41.
2000: Fabiani M E; Dinh D T; Nassis L; Casley D J; Johnston C I
In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
American journal of hypertension 2000;13(9):1005-13.
2000: Farina N K; Johnston C I; Burrell L M
Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
Journal of hypertension 2000;18(6):749-55.
2000: Burrell L M; Risvanis J; Johnston C I; Naitoh M; Balding L C
Vasopressin receptor antagonism--a therapeutic option in heart failure and hypertension.
Experimental physiology 2000;85 Spec No():259S-265S.
2000: Johnston C I
Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
Blood pressure. Supplement 2000;1():9-13.
1999: Koukoulas I; Webb G C; Bottema C D; Gill C; Johnston C I; Aldred G P
Genomic characterization of the sheep vasopressin V1a receptor gene and promoter, with assignment to bands q23-24 of sheep chromosome 3 and cattle chromosome 5.
Gene 1999;240(1):183-92.
1999: Fabiani M E; Johnston C I
Spectrum of use for the angiotensin-receptor blocking drugs.
Current hypertension reports 1999;1(5):394-401.
1999: Risvanis J; Naitoh M; Johnston C I; Burrell L M
In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat.
European journal of pharmacology 1999;381(1):23-30.
1999: Gilbert R E; Wu L L; Kelly D J; Cox A; Wilkinson-Berka J L; Johnston C I; Cooper M E
Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis.
The American journal of pathology 1999;155(2):429-40.
1998: Yoshida K; Kanazawa M; Casley D J; Katopothis A; Johnston C I
Inhibition of kidney neutral endopeptidase after administration of the neutral endopeptidase inhibitor candoxatril: quantitation by autoradiography.
Journal of cardiovascular pharmacology 1998;32(5):702-8.
1998: Tikkanen T; Tikkanen I; Rockell M D; Allen T J; Johnston C I; Cooper M E; Burrell L M
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
Hypertension 1998;32(4):778-85.
1998: Johnston C I; Risvanis J; Naitoh M; Tikkanen I
Mechanism of progression of renal disease: current hemodynamic concepts.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1998;16(4):S3-7.
1998: Yoshida K; Yasujima M; Casley D J; Johnston C I
Effect of chronic neutral endopeptidase inhibition on cardiac hypertrophy after experimental myocardial infarction.
Japanese circulation journal 1998;62(9):680-6.
1998: Yoshida K; Kohzuki M; Casley D J; Johnston C I
Angiotensin-converting enzyme inhibition and salt in experimental myocardial infarction.
Journal of cardiovascular pharmacology 1998;32(3):357-65.
1998: Burrell L M; Phillips P A; Risvanis J; Chan R K; Aldred K L; Johnston C I
Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat.
The American journal of physiology 1998;275(1 Pt 2):H176-82.
1998: Yoshida K; Perich R; Casley D J; Johnston C I
Hypotensive effect of ZD7155, an angiotensin II receptor antagonist, parallels receptor occupancy in two-kidney, one-clip Goldblatt hypertensive rats.
Journal of hypertension 1998;16(5):645-55.
1998: Risvanis J; Johnston C I; Phillips P A; Burrell L M
Vasopressin V1a and V2 receptor mRNA in deoxycorticosterone acetate-salt hypertension in the rat.
Clinical science (London, England : 1979) 1998;94(5):517-23.
1998: Naitoh M; Power J; Phillips P A; Risvanis J; Johnston C I; Burrell L M
Effects of chronic AVP V2R blockade in congestive heart failure in sheep. Comparison with chronic ACE inhibition.
Advances in experimental medicine and biology 1998;449():445-6.
1998: Jandeleit-Dahm K; Burrell L M; Kanazawa M; Casley D; Jackson B; Johnston C I
Effects of neutral endopeptidase inhibition in the rat remnant kidney model.
Kidney & blood pressure research 1998;21(6):419-24.
1998: Johnston C I; Naitoh M; Risvanis J; Farina N; Burrell L M
New hormonal blockade strategies in cardiovascular disease.
Scandinavian cardiovascular journal. Supplement 1998;47():61-6.
1997: Johnston C I; Naitoh M; Burrell L M
Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1997;15(7):S3-6.
1997: Johnston C I; Risvanis J
Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues.
American journal of hypertension 1997;10(12 Pt 2):306S-310S.
1997: Tikkanen I; Johnston C I
Comparison of renin-angiotensin to calcium channel blockade in renal disease.
Kidney international. Supplement 1997;63():S19-22.
1997: Burrell L M; Farina N; Risvanis J; Woollard D; Casely D; Johnston C I
Inhibition of neutral endopeptidase, the degradative enzyme for natriuretic peptides, in rat kidney after oral SCH 42495.
Clinical science (London, England : 1979) 1997;93(1):43-50.
1997: Burrell L M; Risvanis J; Phillips P A; Naitoh M; Johnston C I
Chronic vasopressin antagonism in two-kidney, one-clip renovascular hypertension.
Clinical and experimental hypertension (New York, N.Y. : 1993) 1997;19(5-6):981-91.
1997: Jandeleit-Dahm K; Burrell L M; Johnston C I; Koch K M
Elevated vascular angiotensin converting enzyme mediates increased neointima formation after balloon injury in spontaneously hypertensive rats.
Journal of hypertension 1997;15(6):643-50.
1997: Burrell L M; Johnston C I
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
Drugs & aging 1997;10(6):421-34.
1997: Naitoh M; Burrell L M; Risvanis J; Aldred K L; Rockell M D; Johnston C I; Phillips P A
Modulation of genetic hypertension by short-term AVP V1A or V2 receptor antagonism in young SHR.
The American journal of physiology 1997;272(2 Pt 2):F229-34.
1996: Kohzuki M; Kanazawa M; Yoshida K; Kamimoto M; Wu X M; Jiang Z L; Yasujima M; Abe K; Johnston C I; Sato T
Cardiac angiotensin converting enzyme and endothelin receptor in rats with chronic myocardial infarction.
Japanese circulation journal 1996;60(12):972-80.
1996: Hulthén U L; Cao Z; Rumble J R; Cooper M E; Johnston C I
Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
American journal of hypertension 1996;9(9):895-901.
1996: Black M J; Bertram J F; Johnston C I
Cardiac growth during high and low dose perindopril treatment in spontaneously hypertensive rats.
Clinical and experimental pharmacology & physiology 1996;23(6-7):605-7.
1996: Burrell L M; Chan R; Phillips P A; Calafiore P; Tonkin A M; Johnston C I
Validation of an echocardiographic assessment of cardiac function following moderate size myocardial infarction in the rat.
Clinical and experimental pharmacology & physiology 1996;23(6-7):570-2.
1996: Johnston C I
Future management of high blood pressure.
Journal of cardiovascular pharmacology 1996;27 Suppl 3():S55-60.
1995: Liu J J; Chen J R; Buxton B B; Johnston C I; Burrell L M
Potent inhibitory effect of SR 49059, an orally active non-peptide vasopressin VIa receptor antagonist, on human arterial coronary bypass graft.
Clinical science (London, England : 1979) 1995;89(5):481-5.
1995: Burrell L M; Phillips P A; Risvanis J; Aldred K L; Hutchins A M; Johnston C I
Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism.
Hypertension 1995;26(5):828-34.
1995: Johnston C I
Angiotensin receptor antagonists: focus on losartan.
Lancet 1995;346(8987):1403-7.
1995: Cooper M E; McNally P G; Phillips P A; Johnston C I
Amylin stimulates plasma renin concentration in humans.
Hypertension 1995;26(3):460-4.
1995: Hutchins A M; Phillips P A; Venter D J; Burrell L M; Johnston C I
Molecular cloning and sequencing of the gene encoding a sheep arginine vasopressin type 1a receptor.
Biochimica et biophysica acta 1995;1263(3):266-70.
1995: Phillips P A; Risvanis J; Hutchins A M; Burrell L M; MacGregor D; Gundlach A L; Johnston C I
Down-regulation of vasopressin V1a receptor mRNA in diabetes mellitus in the rat.
Clinical science (London, England : 1979) 1995;88(6):671-4.
1995: Burrell L M; Johnston C I
Beyond ACE inhibition: new developments in drug therapy for hypertension.
The Medical journal of Australia 1995;162(12):659-61.
1995: Johnston C I; Burrell L M
Evolution of blockade of the renin-angiotensin system.
Journal of human hypertension 1995;9(6):375-80.
1995: Jandeleit-Dahm K; Jackson B; Paxton D; Perich R; Johnston C I
Characterisation of angiotensin converting enzyme from different rat vascular beds.
Blood pressure 1995;4(3):170-6.
1995: Hulthén U L; Rumble J; Cooper M E; Johnston C I
Vascular albumin permeability and hypertrophy in a rat model combining streptozotocin-induced diabetes and genetic hypertension.
Journal of hypertension 1995;13(5):529-33.
1995: Larkins R G; Martin T J; Johnston C I
The boundaryless hospital--a commentary.
Australian and New Zealand journal of medicine 1995;25(2):169-70.
1995: Phillips P A; Burrell L M; Tonkin A M; Johnston C I
Congestive cardiac failure and arrhythmias.
The Medical journal of Australia 1995;162(1):44-7.
1995: Liu J J; Chen J R; Bradley C J; Johnston C I; Buxton B F
Induction of Ca2+ signaling and possible exocytosis in endothelial cells by a stable leukocyte-derived factor.
Biochemical and biophysical research communications 1995;206(1):146-52.
1994: Burrell L M; Phillips P A; Rolls K A; Buxton B F; Johnston C I; Liu J J
Vascular responses to vasopressin antagonists in man and rat.
Clinical science (London, England : 1979) 1994;87(4):389-95.
1994: Liu J J; Chen J R; Bradley C J; Xie B; Johnston C I; Buxton B F
Autologous neutrophil derived supernatants inhibit endothelium dependent relaxation in human coronary bypass graft.
Cardiovascular research 1994;28(9):1353-9.
1994: Phillips P A; Hutchins A M; Burrell L M; Risvanis J; Johnston C I
V1-like [Arg8]vasopressin binding sites occur in rat hepatocyte nuclei.
European journal of pharmacology 1994;259(3):325-9.
1994: Burrell L M; Phillips P A; Stephenson J M; Risvanis J; Rolls K A; Johnston C I
Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.
Hypertension 1994;23(6 Pt 1):737-43.
1994: Liu J J; Xie B; Smith I L; Johnston C I; Buxton B F
A stable leukocyte-derived factor inhibits platelet aggregation.
Biochemical and biophysical research communications 1994;201(2):878-82.
1994: Burrell L M; Phillips P A; Stephenson J M; Risvanis J; Johnston C I
Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260).
Blood pressure 1994;3(1-2):137-41.
1994: Johnston C I
Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling.
Hypertension 1994;23(2):258-68.
1994: Perich R B; Jackson B; Johnston C I
Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme.
European journal of pharmacology 1994;266(3):201-11.
1994: Trinder D; Phillips P A; Stephenson J M; Risvanis J; Aminian A; Adam W; Cooper M; Johnston C I
Vasopressin V1 and V2 receptors in diabetes mellitus.
The American journal of physiology 1994;266(2 Pt 1):E217-23.
1994: Jackson B; Liu G; Perich R B; Paxton D; McNicols L; Gutteridge G; Johnston C I
Haemodynamic, renal and hormonal responses to enalkiren in four patients with post-surgical oliguria.
Clinical and experimental pharmacology & physiology 1994;21(2):163-6.
1994: Liu J J; Phillips P A; Burrell L M; Buxton B B; Johnston C I
Human internal mammary artery responses to non-peptide vasopressin antagonists.
Clinical and experimental pharmacology & physiology 1994;21(2):121-4.
1994: Liu J J; Johnston C I; Buxton B F
Synergistic effect of nisoldipine and nitroglycerin on human internal mammary artery.
The Journal of pharmacology and experimental therapeutics 1994;268(1):434-40.
1994: Phillips P A; Burrell L M; Risvanis J; Stephenson J; Johnston C I; Hutchins A M
Effects of anti-emetics on water excretion in humans.
Clinical and experimental pharmacology & physiology 1994;21(1):59-62.
1993: Johnston C I
The place of diuretics in the treatment of hypertension in 1993: can we do better?
Clinical and experimental hypertension (New York, N.Y. : 1993) 1993;15(6):1239-55.
1993: Burrell L M; Phillips P A; Stephenson J; Risvanis J; Hutchins A M; Johnston C I
Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat.
The Journal of endocrinology 1993;138(2):259-66.
1993: Johnston C I; Fabris B; Jandeleit K
Intrarenal renin-angiotensin system in renal physiology and pathophysiology.
Kidney international. Supplement 1993;42():S59-63.
1993: Trinder D; Mooser V; Phillips P A; Smith A I; Casley D; Johnston C I
Monoclonal antibodies to arginine vasopressin receptor bind to liver, kidney and pituitary membranes.
Clinical and experimental pharmacology & physiology 1993;20(6):443-9.
1993: Burrell L M; Phillips P A; Stephenson J; Risvanis J; Hutchins A M; Johnston C I
Effects of an orally active vasopressin V1 receptor antagonist.
Clinical and experimental pharmacology & physiology 1993;20(5):388-91.
1993: Abdelrahman A M; Burrell L M; Johnston C I
Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1993;11(3):S23-6.
1993: Phillips P A; Johnston C I; Gray L
Disturbed fluid and electrolyte homoeostasis following dehydration in elderly people.
Age and ageing 1993;22(1):S26-33.
1992: Johnston C I
Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1992;10(7):S13-26.
1992: Trinder D; Phillips P A; Risvanis J; Stephenson J M; Johnston C I
Regulation of vasopressin receptors in deoxycorticosterone acetate-salt hypertension.
Hypertension 1992;20(4):569-74.
1992: Gao X; Phillips P A; Widdop R E; Trinder D; Jarrott B; Johnston C I
Presence of functional vasopressin V1 receptors in rat vagal afferent neurones.
Neuroscience letters 1992;145(1):79-82.
1992: Perich R B; Jackson B; Rogerson F; Mendelsohn F A; Paxton D; Johnston C I
Two binding sites on angiotensin-converting enzyme: evidence from radioligand binding studies.
Molecular pharmacology 1992;42(2):286-93.
1992: Kanazawa M; Casley D J; Sybertz E J; Haslanger M F; Johnston C I
Localization and characterization of neutral metalloendopeptidase (EC 3.4.24.11), the degradative enzyme for atrial natriuretic peptide, in rat kidney using a radioiodinated neutral metalloendopeptidase inhibitor.
The Journal of pharmacology and experimental therapeutics 1992;261(3):1231-7.
1992: Murohara Y; Johnston C I
Effect of neutral endopeptidase inhibitor in rats with congestive heart failure.
Clinical and experimental pharmacology & physiology 1992;19(5):380-3.
1992: Perich R B; Jackson B; Johnston C I
Variation in angiotensin-converting enzyme (ACE) inhibitor affinity at two binding sites on rat pulmonary ACE: influence on bradykinin hydrolysis.
Clinical and experimental pharmacology & physiology 1992;19(5):353-7.
1992: Jandeleit K; Perich R; Jackson B; Johnston C I
Mesenteric resistance and brain microvascular angiotensin-converting enzyme in the spontaneously hypertensive rat.
Clinical and experimental pharmacology & physiology 1992;19(5):348-52.
1992: Trinder D; Kelly J M; Fernley R; Mooser V; Phillips P A; Johnston C I
Isolation and characterization of the rat liver AVP receptor using [125I][d(CH2)5'sarcosine7]AVP.
Clinical and experimental pharmacology & physiology 1992;19(4):253-60.
1992: Perich R; Jackson B; Paxton D; Johnston C I
Characterization of angiotensin converting enzyme in isolated cerebral microvessels from spontaneously hypertensive and normotensive rats.
Journal of hypertension 1992;10(2):149-53.
1992: Chai S Y; Perich R; Jackson B; Mendelsohn F A; Johnston C I
Acute and chronic effects of angiotensin-converting enzyme inhibitors on tissue angiotensin-converting enzyme.
Clinical and experimental pharmacology & physiology. Supplement 1992;19():7-12.
1992: Johnston C I; Burrell L M; Perich R; Jandeleit K; Jackson B
The tissue renin-angiotensin system and its functional role.
Clinical and experimental pharmacology & physiology. Supplement 1992;19():1-5.
1991: Mooser V; Katopothis A; Casley D; Johnston C I
Cardiac and renal hypertrophy is independent of tissue angiotensin converting enzyme and circulating angiotensin II in hypertensive rats.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1991;9(6):S114-5.
1991: Trinder D; Stephenson J M; Gao X; Phillips P A; Risvanis J; Johnston C I
[3H]desGly-NH2(9)-d(CH2)5[D-Ileu2,Ileu4]AVP: an AVP V2 receptor antagonist radioligand.
Peptides 1991;12(6):1195-200.
1991: Phillips P A; Bretherton M; Johnston C I; Gray L
Reduced osmotic thirst in healthy elderly men.
The American journal of physiology 1991;261(1 Pt 2):R166-71.
1991: Kohzuki M; Johnston C I; Chai S Y; Jackson B; Perich R; Paxton D; Mendelsohn F A
Measurement of angiotensin converting enzyme induction and inhibition using quantitative in vitro autoradiography: tissue selective induction after chronic lisinopril treatment.
Journal of hypertension 1991;9(7):579-87.
1991: Trinder D; Mooser V; Kelly J M; Phillips P A; Casley D; Johnston C I
Characterization of monoclonal antibodies to a rat liver vasopressin receptor.
Clinical and experimental pharmacology & physiology 1991;18(5):345-8.
1991: Mooser V; Casley D; Trinder D; Paxton D L; Johnston C I
Reduction in left ventricular mass in normotensive and spontaneously hypertensive rats given enalapril.
Clinical and experimental pharmacology & physiology 1991;18(5):341-4.
1991: Fabris B; Jackson B; Johnston C I
Salt blocks the renal benefits of ramipril in diabetic hypertensive rats.
Hypertension 1991;17(4):497-503.
1991: Mendelsohn F A; Pupic V; Jackson B; Cubela R; Johnston C I
Acute and chronic effects of perindopril on tissue angiotensin converting enzyme activity.
American journal of hypertension 1991;4(3 Pt 2):220S-225S.
1991: Johnston C I; Mooser V; Sun Y; Fabris B
Changes in cardiac angiotensin converting enzyme after myocardial infarction and hypertrophy in rats.
Clinical and experimental pharmacology & physiology 1991;18(2):107-10.
1991: Howes L G; Hodsman G P; Rowe P R; Johnston C I
Comparative effects of angiotensin converting enzyme inhibition (perindopril) or diuretic therapy on cardiac hypertrophy and sympathetic activity following myocardial infarction in rats.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1991;5(1):147-52.
1991: Arnolda L; McGrath B P; Johnston C I
Systemic and regional effects of vasopressin and angiotensin in acute left ventricular failure.
The American journal of physiology 1991;260(2 Pt 2):H499-506.
1991: Arnolda L; McGrath B P; Johnston C I
Vasopressin and angiotensin II contribute equally to the increased afterload in rabbits with heart failure.
Cardiovascular research 1991;25(1):68-72.
1991: Phillips P A; Hodsman G P; Johnston C I
Neuroendocrine mechanisms and cardiovascular homeostasis in the elderly.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1991;4 Suppl 6():1209-13.
1991: Yamada H; Fabris B; Allen A M; Jackson B; Johnston C I; Mendelsohn A O
Localization of angiotensin converting enzyme in rat heart.
Circulation research 1991;68(1):141-9.
1991: Jackson B; Mendelsohn F A; Johnston C I
Angiotensin-converting enzyme inhibition: prospects for the future.
Journal of cardiovascular pharmacology 1991;18 Suppl 7():S4-8.
1991: Kohzuki M; Chai S Y; Paxinos G; Karavas A; Casley D J; Johnston C I; Mendelsohn F A
Localization and characterization of endothelin receptor binding sites in the rat brain visualized by in vitro autoradiography.
Neuroscience 1991;42(1):245-60.
1990: Fabris B; Yamada H; Cubela R; Jackson B; Mendelsohn F A; Johnston C I
Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats.
British journal of pharmacology 1990;100(3):651-5.
1990: Kelly J M; Trinder D; Phillips P A; Casley D J; Kemp B; Mooser V; Johnston C I
Vasopressin antisense peptide interactions with the V1 receptor.
Peptides 1990;11(4):857-62.
1990: Fabris B; Jackson B; Kohzuki M; Perich R; Johnston C I
Increased cardiac angiotensin-converting enzyme in rats with chronic heart failure.
Clinical and experimental pharmacology & physiology 1990;17(4):309-14.
1990: Phillips P A; Widdop R E; Chai S Y; Kelly J; Mooser V; Trinder D; Johnston C I
Reduced V1 vasopressin binding in the rat nucleus solitarii after nodose ganglionectomy.
Clinical and experimental pharmacology & physiology 1990;17(4):321-5.
1990: Phillips P A; Abrahams J M; Kelly J M; Mooser V; Trinder D; Johnston C I
Localization of vasopressin binding sites in rat tissues using specific V1 and V2 selective ligands.
Endocrinology 1990;126(3):1478-84.
1990: Jackson B; Fabris B; Paxton D; Franze L; Johnston C I
High salt diet ameliorates effects of angiotensin converting enzyme inhibition in spontaneously hypertensive streptozotocin diabetic rats.
Clinical and experimental pharmacology & physiology 1990;17(3):229-34.
1990: Jackson B; Franze L; Sumithran E; Johnston C I
Pharmacologic nephrectomy with chronic angiotensin converting enzyme inhibitor treatment in renovascular hypertension in the rat.
The Journal of laboratory and clinical medicine 1990;115(1):21-7.
1990: Liu J J; Kelly J; Casley D J; Johnston C I; Nayler W G
Solubilization and characterization of endothelin-1 receptors in rat cardiac tissue.
Biochemical and biophysical research communications 1990;166(1):299-307.
1990: Johnston C I
Biochemistry and pharmacology of the renin-angiotensin system.
Drugs 1990;39 Suppl 1():21-31.
1990: Fabris B; Chen B Z; Pupic V; Perich R; Johnston C I
Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue.
Journal of cardiovascular pharmacology 1990;15 Suppl 2():S6-13.
1989: Johnston C I; Hodsman P G; Kohzuki M; Casley D J; Fabris B; Phillips P A
Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists.
The American journal of medicine 1989;87(6B):24S-28S.
1989: Johnston C I; Fabris B; Yamada H; Mendelsohn F A; Cubela R; Sivell D; Jackson B
Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1989;7(5):S11-6.
1989: Jackson B; Johnston C I
Angiotensin-converting enzyme inhibition in renal disease; contrasting effects on renal function in renal artery stenosis and progressive renal injury.
Journal of human hypertension 1989;3 Suppl 1():107-15.
1989: Fabris B; Jackson B; Cubela R; Mendelsohn F A; Johnston C I
Angiotensin converting enzyme in the rat heart: studies of its inhibition in vitro and ex vivo.
Clinical and experimental pharmacology & physiology 1989;16(4):309-13.
1989: Kohzuki M; Johnston C I; Chai S Y; Casley D J; Rogerson F; Mendelsohn F A
Endothelin receptors in rat adrenal gland visualized by quantitative autoradiography.
Clinical and experimental pharmacology & physiology 1989;16(4):239-42.
1989: Trahair J F; Gall J A; Alcorn D; Coghlan J P; Fernley R; Penschow J; Grattage L P; Johnston C I; Ryan G B
Immunohistochemical study of peripolar cells of the sheep.
Journal of anatomy 1989;162():125-32.
1989: Howes L G; Hodsman G P; Rowe P R; Sumithran E; Johnston C I
Cardiac 3,4-dihydroxyphenylethylene glycol (DHPG) and catecholamine levels during perindopril therapy of chronic left ventricular failure in rats.
Journal of autonomic pharmacology 1989;9(1):15-21.
1989: Phillips P A; Sasadeus J; Hodsman G P; Horowitz J; Saltups A; Johnston C I
Plasma atrial natriuretic peptide in patients with acute myocardial infarction: effects of streptokinase.
British heart journal 1989;61(2):139-43.
1989: Kohzuki M; Hodsman G P; Johnston C I
Attenuated response to atrial natriuretic peptide in rats with myocardial infarction.
The American journal of physiology 1989;256(2 Pt 2):H533-8.
1989: Howes L G; Hodsman G P; Maccarrone C; Kohzuki M; Johnston C I
Cardiac 3,4-dihydroxyphenylethylene glycol (DHPG) and catecholamine levels in a rat model of left ventricular failure.
Journal of cardiovascular pharmacology 1989;13(2):348-52.
1989: Kohzuki M; Johnston C I; Chai S Y; Casley D J; Mendelsohn F A
Localization of endothelin receptors in rat kidney.
European journal of pharmacology 1989;160(1):193-4.
1989: Johnston C I; Jackson B; Cubela R; Sivell D; Kozhuki M
Pharmacokinetics of angiotensin converting enzyme inhibitors in plasma and tissue using radioinhibitor binding and displacement assays.
Advances in experimental medicine and biology 1989;247A():29-34.
1989: Kelly J M; Abrahams J M; Phillips P A; Mendelsohn F A; Grzonka Z; Johnston C I
[125I]-[d(CH2)5, Sar7]AVP: a selective radioligand for V1 vasopressin receptors.
Journal of receptor research 1989;9(1):27-41.
1989: Kohzuki M; Hodsman G P; Harrison R W; Western P S; Johnston C I
Atrial natriuretic peptide infusion in chronic heart failure in the rat.
Journal of cardiovascular pharmacology 1989;13 Suppl 6():S43-6.
1988: Phillips P A; Abrahams J M; Kelly J; Paxinos G; Grzonka Z; Mendelsohn F A; Johnston C I
Localization of vasopressin binding sites in rat brain by in vitro autoradiography using a radioiodinated V1 receptor antagonist.
Neuroscience 1988;27(3):749-61.
1988: Phillips P A; Kelly J M; Abrahams J M; Grzonka Z; Paxinos G; Mendelsohn F A; Johnston C I
Vasopressin receptors in rat brain and kidney: studies using a radio-iodinated V1 receptor antagonist.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1988;6(4):S550-3.
1988: Jackson B; Cubela R B; Johnston C I
Effects of perindopril on angiotensin converting enzyme in tissues of the rat.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1988;6(3):S51-4.
1988: Johnston C I; Mendelsohn F A; Cubela R B; Jackson B; Kohzuki M; Fabris B
Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1988;6(3):S17-22.
1988: Hodsman G P; Sumithran E; Harrison R W; Johnston C I
Cardiac hypertrophy and salt status in chronic myocardial infarction in the rat: effects of enalapril versus salt restriction.
Journal of cardiovascular pharmacology 1988;12(4):467-72.
1988: Sakaguchi K; Chai S Y; Jackson B; Johnston C I; Mendelsohn F A
Differential angiotensin-converting enzyme inhibition in brain after oral administration of perindopril demonstrated by quantitative in vitro autoradiography.
Neuroendocrinology 1988;48(3):223-8.
1988: Hodsman G P; Kohzuki M; Howes L G; Sumithran E; Tsunoda K; Johnston C I
Neurohumoral responses to chronic myocardial infarction in rats.
Circulation 1988;78(2):376-81.
1988: Jackson B; Hodsman P; Johnston C I
Changes in the renin-angiotensin system, exchangeable body sodium, and plasma and atrial content of atrial natriuretic factor during evolution of chronic renal failure in the rat.
American journal of hypertension 1988;1(3 Pt 1):298-300.
1988: Jackson B; Cubela R B; Sakaguchi K; Johnston C I
Characterization of angiotensin converting enzyme (ACE) in the testis and assessment of the in vivo effects of the ACE inhibitor perindopril.
Endocrinology 1988;123(1):50-5.
1988: Hodsman G P; Harrison R W; Sumithran E; Johnston C I
Atrial natriuretic peptide and total exchangeable body sodium: relationships in rats with chronic myocardial infarction.
Clinical science (London, England : 1979) 1988;74(6):659-63.
1988: Jackson B; Cubela R B; Conway E L; Johnston C I
Lisinopril pharmacokinetics in chronic renal failure.
British journal of clinical pharmacology 1988;25(6):719-24.
1988: Jackson B; Johnston C I
The contribution of systemic hypertension to progression of chronic renal failure in the rat remnant kidney: effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor.
Journal of hypertension 1988;6(6):495-501.
1988: Doyle A E; Johnston C I
Australasian contributions to research into hypertension.
Australian and New Zealand journal of medicine 1988;18(3):245-9.
1988: Kohzuki M; Hodsman G P; Harrison R W; Johnston C I
Attenuated renal response to atrial natriuretic peptide infusion in rats with heart failure.
Clinical and experimental pharmacology & physiology 1988;15(4):323-6.
1988: Marchingo A J; Abrahams J M; Woodcock E A; Smith A I; Mendelsohn F A; Johnston C I
Properties of [3H]1-desamino-8-D-arginine vasopressin as a radioligand for vasopressin V2-receptors in rat kidney.
Endocrinology 1988;122(4):1328-36.
1988: Johnston C I; Hodsman G P; Harrison R W; Mendelsohn F A; Tsunoda K
Regulation of cardiac preload by atrial natriuretic peptide in congestive cardiac failure.
The American journal of medicine 1988;84(3A):105-11.
1988: Sakaguchi K; Chai S Y; Jackson B; Johnston C I; Mendelsohn F A
Inhibition of tissue angiotensin converting enzyme. Quantitation by autoradiography.
Hypertension 1988;11(3):230-8.
1988: Johnston C I; Cubela R; Jackson B
Relative inhibitory potency and plasma drug levels of angiotensin converting enzyme inhibitors in the rat.
Clinical and experimental pharmacology & physiology 1988;15(2):123-9.
1988: Jackson B; Maher D; Matthews P G; McGrath B P; Johnston C I
Lack of cross sensitivity between captopril and enalapril.
Australian and New Zealand journal of medicine 1988;18(1):21-7.
1988: Tsunoda K; Mendelsohn F A; Sexton P M; Chai S Y; Hodsman G P; Johnston C I
Decreased atrial natriuretic peptide binding in renal medulla in rats with chronic heart failure.
Circulation research 1988;62(1):155-61.
1987: McGrath B P; Blake D; Jover B; Arnolda L; Ogawa K; Hodsman G P; Johnston C I
Atrial natriuretic peptide release in the rabbit is independent of cardiac nerve activity.
Clinical and experimental pharmacology & physiology 1987;14(9):695-702.
1987: Johnston C I; Arnolda L F; Tsunoda K; Phillips P A; Hodsman G P
Responses of vasoactive hormones in congestive cardiac failure.
Canadian journal of physiology and pharmacology 1987;65(8):1706-11.
1987: Jackson B; Cubela R; Sakaguchi K; Johnston C I
Pharmacokinetics of angiotensin converting enzyme inhibition in tissues following oral lisinopril: studies in the rat using quantitative radioinhibitor binding.
Clinical and experimental pharmacology & physiology 1987;14(4):343-7.
1987: Hodsman G P; Jackson B; Debrevi L M; Ogawa K; Johnston C I
Atrial natriuretic factor in chronic renal failure: studies in man and the rat.
Clinical and experimental pharmacology & physiology 1987;14(3):247-51.
1987: Sakaguchi K; Chai S Y; Jackson B; Johnston C I; Mendelsohn F A
Blockade of angiotensin converting enzyme in circumventricular organs of the brain after oral lisinopril administration demonstrated by quantitative in vitro autoradiography.
Clinical and experimental pharmacology & physiology 1987;14(3):155-8.
1987: Jackson B; McGrath B P; Johnston C I
Hormonal and blood pressure responses to tilting in beta-blocked essential hypertension treated with felodipine or prazosin.
Drugs 1987;34 Suppl 3():87-92.
1987: Jackson B; Cubela R; Johnston C I
Tissue angiotensin converting enzyme (ACE) during changes in the renin-angiotensin system.
Journal of cardiovascular pharmacology 1987;10 Suppl 7():S137-40.
1987: Jackson B; Cubela R; Debrevi L; Whitty M; Johnston C I
Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat.
Journal of cardiovascular pharmacology 1987;10 Suppl 10():S167-9.
1986: Tsunoda K; Hodsman G P; Sumithran E; Johnston C I
Atrial natriuretic peptide in chronic heart failure in the rat: a correlation with ventricular dysfunction.
Circulation research 1986;59(3):256-61.
1986: Jackson B; McGrath B P; Matthews P G; Wong C; Johnston C I
Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension.
Hypertension 1986;8(8):650-4.
1986: Jackson B; Debrevi L; Cubela R; Whitty M; Johnston C I
Preservation of renal function in the rat remnant kidney model of chronic renal failure by blood pressure reduction.
Clinical and experimental pharmacology & physiology 1986;13(4):319-23.
1985: McGrath B P; Arnolda L; Matthews P G; Jackson B; Jennings G; Kiat H; Johnston C I
Controlled trial of enalapril in congestive cardiac failure.
British heart journal 1985;54(4):405-14.
1984: Jackson B; Matthews P G; McGrath B P; Johnston C I
Angiotensin converting enzyme inhibition in renovascular hypertension: frequency of reversible renal failure.
Lancet 1984;1(8370):225-6.
1983: Jackson B; Matthews P G; McGrath B P; Johnston C I; Ada A; Wong C
Renovascular hypertension.
The Medical journal of Australia 1983;2(10):476-7.
1983: Clappison B H; Anderson W P; Johnston C I
Renal kinins and renal haemodynamics.
Advances in experimental medicine and biology 1983;156 (Pt B)():969-75.
1982: Johnston C I; Clappison B H; Anderson W P; Yasujima M
Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels.
The American journal of cardiology 1982;49(6):1401-4.
1982: Johnston C I; McGrath B P; Matthews P G; Jackson B
Treatment of hypertension with angiotensin converting enzyme inhibitors.
Clinical and experimental pharmacology & physiology. Supplement 1982;7():135-44.
1981: Clappison B H; Anderson W P; Johnston C I
Renal hemodynamics and renal kinins after angiotensin-converting enzyme inhibition.
Kidney international 1981;20(5):615-20.
1981: Clappison B H; Anderson W P; Johnston C I
Role of the kallikrein-kinin system in the renal effects of angiotensin-converting enzyme inhibition in anaesthetized dogs.
Clinical and experimental pharmacology & physiology 1981;8(5):509-13.
1981: McGrath B P; Matthews P G; Johnston C I
Use of captopril in the diagnosis of renal hypertension.
Australian and New Zealand journal of medicine 1981;11(4):359-63.
1981: Millar J A; McGrath B P; Matthews P G; Johnston C I
Acute effects of captopril on blood pressure and circulating hormone levels in salt-replete and depleted normal subjects and essential hypertensive patients.
Clinical science (London, England : 1979) 1981;61(1):75-83.
1981: Johnston C I; Iansek R; Millar J A; McGrath B P; Matthews P G
Vasoactive peptides and hypertension: role of angiotensin converting enzyme.
Australian and New Zealand journal of medicine 1981;11(Suppl 1):59-63.
1980: McGrath B P; Matthews P G; Johnston C I
Acute changes in blood pressure and vasoactive hormones after captopril in hypertensive patients.
Clinical and experimental pharmacology & physiology 1980;7(5):487-91.
1980: Clappison B H; Millar J A; Casley D J; Anderson W P; Johnston C I
Renal, adrenal and vascular changes during inhibition of converting enzyme with captopril.
Clinical and experimental pharmacology & physiology 1980;7(5):493-8.
1980: Johnston C I; Millar J A; Casley D J; McGrath B P; Matthews P G
Hormonal responses to angiotensin blockade. Comparison between receptor antagonism and converting enzyme inhibition.
Circulation research 1980;46(6 Pt 2):I128-34.
1980: Johnston C I; Clappison B; McGrath B P; Matthews P G; Millar J A; Anderson W P
Kallikrein, kinins and blood pressure - effects of angiotensin-converting enzyme inhibition.
Progress in biochemical pharmacology 1980;17():123-33.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Colin Johnston

Research Profile (preview)

Living Beings

Chemicals & Drugs

Anatomy

Disorders

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Colin Johnston (preview)

All Publications